Patent ID: 11957693
Assignee: GILEAD SCIENCES, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A | IPC A

Claim 0:
1. A method of treating a TROP-2 expressing cancer comprising:
administering to a human patient in need a therapeutically effective amount of gemcitabine, and a therapeutically effective amount of an MCL-1 inhibitor;
wherein the MCL-1 inhibitor is of formula (I):, , or a pharmaceutically acceptable salt thereof;
wherein R1 is 5-10 membered heteroaryl containing 1-2 heteroatoms; wherein each heteroatom is independently selected from nitrogen, sulfur, and oxygen;
the 5-10 membered heteroaryl of R1 is optionally substituted with 1-3 substituents independently selected from halo, hydroxyl, —CN, C1-6alkyl, C1-6haloalkyl, —ORa, and C3-6cycloalkyl; and
each R2, R3, R4, and R5 is independently hydrogen or C1-6alkyl;
R6 is hydrogen or halo; and
Ra is independently hydrogen, C1-6alkyl, C2-6alkenyl, and C3-10cycloalkyl.